Omeros (NASDAQ:OMER) Earns Buy Rating from D. Boral Capital

by · The Cerbat Gem

Omeros (NASDAQ:OMER – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at D. Boral Capital in a note issued to investors on Thursday,Benzinga reports. They presently have a $36.00 target price on the biopharmaceutical company’s stock. D. Boral Capital’s price objective indicates a potential upside of 155.50% from the company’s previous close.

Several other equities analysts also recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a report on Wednesday, October 8th. WBB Securities reiterated a “strong-buy” rating and issued a $45.00 target price on shares of Omeros in a research note on Wednesday, October 15th. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Wednesday, October 15th. Wall Street Zen raised Omeros from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Finally, HC Wainwright boosted their price objective on Omeros from $20.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Omeros has an average rating of “Moderate Buy” and a consensus price target of $40.33.

Get Our Latest Analysis on Omeros

Omeros Trading Up 4.1%

NASDAQ OMER opened at $14.09 on Thursday. The stock’s 50 day moving average is $10.36 and its two-hundred day moving average is $6.52. The company has a market capitalization of $998.98 million, a price-to-earnings ratio of -6.98 and a beta of 2.38. Omeros has a 1-year low of $2.95 and a 1-year high of $17.65.

Omeros (NASDAQ:OMER – Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.39. On average, analysts predict that Omeros will post -3.09 earnings per share for the current year.

Hedge Funds Weigh In On Omeros

Several hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its position in Omeros by 1,201.1% in the third quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock worth $1,706,000 after purchasing an additional 384,168 shares during the period. Millennium Management LLC raised its stake in shares of Omeros by 49.1% during the third quarter. Millennium Management LLC now owns 401,814 shares of the biopharmaceutical company’s stock worth $1,647,000 after buying an additional 132,393 shares during the last quarter. Brevan Howard Capital Management LP boosted its stake in Omeros by 22.9% in the third quarter. Brevan Howard Capital Management LP now owns 129,393 shares of the biopharmaceutical company’s stock valued at $531,000 after acquiring an additional 24,094 shares during the last quarter. Two Sigma Investments LP grew its holdings in Omeros by 39.3% during the 3rd quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock worth $3,827,000 after acquiring an additional 263,095 shares during the period. Finally, Bridgeway Capital Management LLC raised its position in shares of Omeros by 78.8% during the 3rd quarter. Bridgeway Capital Management LLC now owns 56,715 shares of the biopharmaceutical company’s stock valued at $233,000 after acquiring an additional 25,000 shares during the last quarter. Institutional investors own 48.79% of the company’s stock.

About Omeros

(Get Free Report)

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

See Also